GE Healthcare
Research & Biopharmaceutical Manufacturing - GE Healthcare Life Sciences.
Launch date
Employees
Market cap
€36.1b
Enterprise valuation
€43.0b (Public information from Sep 2024)
Share price
$90.62 GEHC
Munich Bavaria (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 17.2b | 17.6b | 18.3b | 19.6b | 19.8b | 20.8b | 21.9b |
| % growth | 3 % | 2 % | 4 % | 7 % | 1 % | 5 % | 5 % |
| EBITDA | 3.4b | 3.5b | 3.2b | 3.5b | 3.6b | 4.0b | 4.3b |
| % EBITDA margin | 20 % | 20 % | 18 % | 18 % | 18 % | 19 % | 19 % |
| Profit | 13.8b | 2.2b | 1.9b | 1.6b | 1.8b | 2.1b | 2.3b |
| % profit margin | 81 % | 13 % | 10 % | 8 % | 9 % | 10 % | 11 % |
| EV / revenue | - | - | 1.8x | 2.2x | 2.2x | 2.0x | 1.8x |
| EV / EBITDA | - | - | 10.3x | 12.0x | 12.1x | 10.6x | 9.4x |
| R&D budget | 810m | 816m | 1.0b | 1.2b | - | - | - |
| R&D % of revenue | 5 % | 5 % | 6 % | 6 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Corporate spinout | ||
| N/A | N/A | IPO | |
* | $53.0k | Post IPO Equity | |
* | $44.0m | Grant | |
* | N/A | N/A | Secondary |
* | N/A | N/A | Secondary |
| Total Funding | €40.0m | ||
Related Content
Recent News about GE Healthcare
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
